Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: September 9, 2025
Reporting Period: Single event date (September 9, 2025)
Business Context: The Company is a Delaware corporation listed on the Nasdaq Capital Market. It is designated as an emerging growth company. The filing reports a specific corporate event regarding its CyPath® Lung product.
Key Financial Metrics
This Form 8-K filing does not contain financial statements, revenue figures, profit data, cash flow information, margin analysis, debt levels, or liquidity metrics. The document is a current report focused on a non-financial corporate event.
Material Changes
Item 8.01 - Other Events:
- The Company announced the release of a new case study on September 9, 2025.
- The case study demonstrates that the CyPath® Lung product successfully identified cancer in a patient presenting with an incidental finding of ground glass nodules.
- A copy of the press release detailing this event is attached as Exhibit 99.1.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release by reference but does not provide forward-looking guidance, financial outlook, or specific management commentary beyond the announcement of the case study.
Risks and Contingencies: No specific risks, contingencies, or unusual items are disclosed in the text of this filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for full details on the CyPath® Lung case study and the clinical significance of the ground glass nodule finding.
- Verify the Company's status as an emerging growth company and its implications for financial reporting standards.
- Check subsequent filings (e.g., 10-Q or 10-K) for any financial impact or revenue recognition related to this product development milestone.
- Confirm the trading status of Common Stock (BIAF) and Warrants (BIAFW) on the Nasdaq Capital Market.